Login to Your Account



Zafgen shares boosted on phase II findings in rare form of obesity

By Marie Powers
Staff Writer

Wednesday, January 7, 2015

Little more than six months after opening at $20 after pricing its initial public offering, Zafgen Inc. impressed investors by reporting that beloranib met the primary efficacy endpoint of weight reduction in a small phase II trial in patients with hypothalamic injury associated obesity.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription